Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2014British Journal of NeurosurgeryOpen Access

EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers

View Full Paper
Ask AI
Bookmark
Share

Authors

CFClaire FaulknerNorth Bristol NHS TrustAPAbigail PalmerUniversity of PittsburghHWHannah WilliamsRegroupement Québécois sur les Matériaux de Pointe

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Faulkner et al. (2014) studied this question.

synapsesocial.com/papers/6a6561da1b0c8ec2e12d6913https://doi.org/10.3109/02688697.2014.950631
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic relevance of MAPK expression in glioblastoma multiforme2003 · 56 citations
  2. 2Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance2012 · 248 citations
  3. 3Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 260342009 · 577 citations
  4. 4Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients2005 · 517 citations